- Home
- PCYO vs CBIO Comparison
PCYO vs CBIO Comparison
Compare PCYO & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCYO
- CBIO
- Stock Information
- Founded
- PCYO 1976
- CBIO 2003
- Country
- PCYO United States
- CBIO United States
- Employees
- PCYO N/A
- CBIO N/A
- Industry
- PCYO Water Supply
- CBIO
- Sector
- PCYO Utilities
- CBIO
- Exchange
- PCYO Nasdaq
- CBIO Nasdaq
- Market Cap
- PCYO 267.7M
- CBIO 219.5M
- IPO Year
- PCYO N/A
- CBIO N/A
- Fundamental
- Price
- PCYO $11.22
- CBIO $14.12
- Analyst Decision
- PCYO
- CBIO Strong Buy
- Analyst Count
- PCYO 0
- CBIO 5
- Target Price
- PCYO N/A
- CBIO $25.60
- AVG Volume (30 Days)
- PCYO 51.3K
- CBIO 65.8K
- Earning Date
- PCYO 11-12-2025
- CBIO 11-06-2025
- Dividend Yield
- PCYO N/A
- CBIO N/A
- EPS Growth
- PCYO 12.50
- CBIO N/A
- EPS
- PCYO 0.54
- CBIO N/A
- Revenue
- PCYO $26,087,000.00
- CBIO N/A
- Revenue This Year
- PCYO N/A
- CBIO N/A
- Revenue Next Year
- PCYO N/A
- CBIO N/A
- P/E Ratio
- PCYO $20.39
- CBIO N/A
- Revenue Growth
- PCYO N/A
- CBIO N/A
- 52 Week Low
- PCYO $9.65
- CBIO $9.81
- 52 Week High
- PCYO $14.63
- CBIO $21.40
- Technical
- Relative Strength Index (RSI)
- PCYO 60.70
- CBIO 68.13
- Support Level
- PCYO $10.73
- CBIO $12.76
- Resistance Level
- PCYO $11.22
- CBIO $13.43
- Average True Range (ATR)
- PCYO 0.23
- CBIO 0.55
- MACD
- PCYO 0.01
- CBIO 0.09
- Stochastic Oscillator
- PCYO 68.59
- CBIO 68.41
About PCYO Pure Cycle Corporation
Pure Cycle Corp is a diversified land and water resource development company. The company designs, constructs, manages, operates, and maintains water and wastewater systems. The firm operates in two business segments namely Water and wastewater resource development and Land development. It generates maximum revenue from the Land development segment. The land resource development segment includes all the activities necessary to develop and sell finished lots.
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.